INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...

Eli Lilly's Emgality didn't just hit the next-generation migraine market in third place behind Amgen and Novartis' Aimovig and Teva's Ajovy. It's been trailing its CGRP rivals in early sales results, ...

INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...

The Food and Drug Administration (FDA) on Tuesday announced they had signed off on Emgality, an episodic cluster headache treatment that’s the first of its kind to be approved by the federal agency.

As many as 1 million Americans who may suffer with cluster headaches may finally get some relief with the approval of the first drug specifically designed to treat the rare but devastating condition ...

England's drug cost watchdogs have not been gentle on companies marketing hot but expensive new CGRP inhibitors to treat migraine headaches. But they just made an exception for one of those companies: ...

INDIANAPOLIS, June 15, 2021 /PRNewswire/ -- To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) compared to ...

The FDA approved Emgality for treatment of episodic cluster headache in adults. Emgality (galcanezumab-gnlm, Eli Lilly) is the first drug approved for the condition. “The FDA is committed to ...